Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. IN496/DELNP/2005 - A PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ATYPICAL DEPRESSION

Office
Inde
Numéro de la demande 496/DELNP/2005
Date de la demande 09.02.2005
Numéro de publication 496/DELNP/2005
Date de publication 26.03.2010
Type de publication A
CIB
A61K 31/65
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
31Préparations médicinales contenant des ingrédients actifs organiques 
65Tétracyclines 
Déposants CYPRESS BIOSCIENCE, INC
Inventeurs RAO, SRINIVAS, G.
KRANZLER, JAY D.
Données relatives à la priorité 60/398,676 24.07.2002 US
60/443,035 28.01.2003 US
Titre
(EN) A PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ATYPICAL DEPRESSION
Abrégé
(EN) Methods for the prevention or treatment of atypical depression secondary to pain (DSP) have been developed. The method generally involves administering an effective amount of a monoamine re uptake inhibitor to treat or prevent symptoms of DSP. In a preferred embodiment, a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor (SRNI) compound of a specific type, or a pharmaceutically acceptable sait thereof is administered. The most preferred SNRI compounds are non-tricyclic SNRIs, wherein serotonin reuptake inhibition is greater than norepinephrine reuptake inhibition; and NSRIs, wherein norepinephrine reuptake inhibition is greater than serotonin reuptake inhibition. The most preferred compound is milnacipran or a bioequivalent or pharmaceutically acceptable salt thereof. Other preferred compounds are duloxetine and venlafaxine or a bioequivalent or pharmaceutically acceptable salt thereof. In yet another embodiment, a therapeutically effective amount of a non-tricyclic triple reuptake inhibitor ("TRI") compound of a specific type, or a pharmaceutically acceptable salt thereof, is administered. The TRI compounds are characterized by their ability to block the reuptake (and, hence, increase central concentrations of ) the three primary brain monoamines: serotonin, noradrenaline, and dopamine.